Clinical Trials Logo

Schizophrenic Disorder clinical trials

View clinical trials related to Schizophrenic Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT03010865 Withdrawn - Clinical trials for Cognitive Impairment

Sodium Butyrate For Improving Cognitive Function In Schizophrenia

Start date: June 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this grant is to evaluate the efficacy of sodium butyrate as a novel treatment for cognitive deficits in schizophrenia (SZ). The aims will be to evaluate its effects on improving symptoms and functioning in SZ, and the relationship of the drug's clinical effects to epigenetic and inflammation related biochemical changes.

NCT ID: NCT01852331 Completed - Schizophrenia Clinical Trials

Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia

PGD-RCT
Start date: January 2013
Phase: Phase 2
Study type: Interventional

The investigators hypothesize that Peony-Glycyrrhiza Decoction (PGD) adjunctive therapy could reduce the incidence of prolactin (PRL)-related adverse events in patients with schizophrenia and suppress antipsychotic-induced elevation of PRL levels. This is a placebo-controlled trial conducted in schizophrenic patients to determine whether PGD adjunctive treatment could produce greater biochemical and clinical improvement on hyperprolactinemia (hyperPRL) compared to placebo treatment.

NCT ID: NCT00206115 Completed - Clinical trials for Schizophrenic Disorder

SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The purpose of this 6-week study is to determine whether treatment with Seroquel® Sustained Release (SR) is more effective than placebo in the treatment of acute schizophrenia. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

NCT ID: NCT00018837 Completed - Schizophrenia Clinical Trials

Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome

Start date: April 1998
Phase: N/A
Study type: Interventional

The goal of this research program is to implement a series of psychoeducational training classes designed to teach individuals with schizophrenia the importance of medication treatment, how to identify and manage medication side effects, and how to make appointments and emergency plans. The skills taught to the research subjects will lead to demonstrable increases (compared to the control group) in adherence to both the prescribed medication regimen and scheduled outpatient appointments and thereby cause a decrease (again compared to the control group) in rehospitalization rates and bed-days during subsequent twelve months following the intervention. A secondary objective of this work is that if the CREP program is successful and/or illness education is effective, the data will be able to disseminated throughout the VISN 22 via the recently awarded Mental Illness Research Education and Clinical Center (MIRECC) program.